CoChat

The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD

Open access
Shin, Jung-Im, Sang, Yingying, Chang, Alex R., Dunning, Stephan C., Coresh, Josef, Inker, Lesley A., Selvin, Elizabeth, Ballew, Shoshana H., Grams, Morgan E. · 2020 · Journal of the American Society of Nephrology
Cited by 38

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Significance Statement: Because race and sex affect serum creatinine levels independently of GFR, the Food and Drug Administration’s previous creatinine-based metformin contraindication may have inadvertently caused racial and sex disparities in metformin prescription among patients with diabetes and moderate kidney dysfunction. It is unknown whether these disparities were mitigated after a 2016 labeling change to an eGFR-based contraindication. The authors found that before the labeling change, among patients with eGFR of 30–44 ml/min per 1.73 m 2, Black patients and men were underprescribed metformin for diabetes compared with White patients and women, respectively. Racial and sex disparities were attenuated in patients with eGFR of 30–44 ml/min per 1.73 m 2 after the label change. These results suggest that drug dosing recommendations solely on the basis of serum creatinine may cause racial and sex disparities in its use. Background: In 2016, the Food and Drug Administration (FDA) changed labeling regarding metformin contraindications in patients with diabetes and CKD from using serum creatinine–based thresholds to using eGFR-based thresholds. Because race and sex affect serum creatinine levels independently of GFR, the earlier creatinine-based contraindication may have inadvertently caused racial and sex disparities in metformin prescription among patients with low eGFR. Methods: In an analysis of 15,946 Black and White primary care patients with diabetes and eGFR≥30 ml/min per 1.73 m 2 in a large health system (the primary cohort), we assessed the association of race and sex with metformin prescription across eGFR level before and after the FDA label change. For a replication cohort, we meta-analyzed data from 36 cohorts with 1,051,723 patients from OptumLabs Data Warehouse. Results: In the primary cohort, before the label change, Black patients with eGFR of 30–44 ml/min per 1.73 m 2 were prescribed metformin less often than White counterparts (adjusted prevalence ratio [aPR], 0.65; 95% confidence interval [95% CI], 0.52 to 0.82); this disparity was significantly attenuated after the label change (aPR, 0.90; 95% CI, 0.74 to 1.09; P value for interaction by period =0.04). Results were consistent in the replication cohorts. Men with eGFR of 30–44 ml/min per 1.73 m 2 received metformin prescriptions less often than women counterparts before the label change; this was nonsignificantly attenuated after the label change, but we found significant attenuation in the replication cohorts (aPR pre-label change, 0.76; 95% CI, 0.73 to 0.79; aPR post-label change, 0.85; 95% CI, 0.83 to 0.88; P value for interaction by period <0.001). Conclusions: The metformin label change to an eGFR-based contraindication may have reduced racial and sex disparities in metformin prescription in moderate kidney dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2019101119

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 38

Metadata

Authors
Shin, J.-I., Sang, Y., Chang, A. R., Dunning, S. C., Coresh, J., Inker, L. A., Selvin, E., Ballew, S. H., & Grams, M. E.
Venue
Journal of the American Society of Nephrology
Published
2020-07-13
Volume
31
Issue
8
Pages
1847-1858
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W3042894330
Cited by
38
References
12
FWCI
3.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. https://app.cochat.ai/papers/10.1681/asn.2019101119
The paper
Shin, J.-I., Sang, Y., Chang, A. R., Dunning, S. C., Coresh, J., Inker, L. A., Selvin, E., Ballew, S. H., & Grams, M. E. (2020). The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2019101119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.